As we navigate the ongoing battle against influenza, it's crucial to stay informed about the evolving trends and challenges in vaccine administration. This season, we're facing a unique set of circumstances, from new strains to funding changes, which demand our attention and proactive measures.
The Flu Season's Early Toll
The flu season has already claimed 112 lives this year, a stark reminder of the disease's severity. With over 25,000 recorded cases in the first quarter of 2026, and a whopping 48,641 cases in the same period last year, it's clear that influenza remains a significant public health concern.
Vaccine Uptake: A Slow Start
One of the key concerns this season is the slow uptake of flu vaccines, particularly among priority groups. While older Australians aged 75 and over have the highest vaccination rates, young children aged 2-4 years, who are at high risk of severe complications, have alarmingly low vaccination rates, with some jurisdictions reporting coverage below 1%. This disparity highlights the need for targeted strategies to reach these vulnerable groups.
Pertussis: Not Just a Childhood Illness
A recent advisory from the Australian Technical Advisory Group on Immunisation (ATAGI) serves as a reminder that pertussis, or whooping cough, is not exclusive to childhood. In fact, older adults and individuals with chronic illnesses are at higher risk of morbidity and mortality from this disease. ATAGI recommends that adults over 65 receive a dose of dTpa every 10 years. Pharmacists should ensure they inquire about or check patients' vaccination records when administering other vaccines, such as influenza or COVID-19, to ensure pertussis protection is up to date.
Funding Changes and State Programs
The funding landscape for flu vaccines has become more complex this season, with various state-based programs offering funded vaccines. Pharmacists must be vigilant in ensuring they use the correct stock and claiming process via the Pharmacy Programs Administrator (PPA). Incorrect claims can lead to stock discrepancies and compliance issues. Medadvisor's recent guidance update for recording funding sources in clinical systems further emphasizes the need for accuracy in this regard.
Needle-Free Option: FluMist in WA
In a positive development, the Western Australian government has made FluMist, the intranasal influenza vaccine, available to children aged 2-11 years through local pharmacies. With 130,000 doses available, this needle-free option is expected to boost vaccination rates among young children. The PSA's encouragement of this choice-based approach aims to make influenza protection more accessible for families.
Conclusion
This influenza season presents unique challenges, from new strains to funding complexities. As an expert in the field, I believe it's crucial to stay vigilant, adapt to changing circumstances, and ensure that our vaccination strategies are effective and accessible to all. By staying informed and proactive, we can make a significant impact on public health and reduce the toll of influenza.
